Which has better valuation and earnings, EHC or MEDP?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Encompass Health $5.94B 2.32 $566.20M $6.40 21.96 Medpace $2.53B 7.15 $451.12M $18.04 35.84

Does the media favor EHC or MEDP?

In the previous week, Encompass Health and Encompass Health both had 5 articles in the media. Medpace's average media sentiment score of 1.29 beat Encompass Health's score of 1.04 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ELV or MEDP?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elevance Health $199.13B 0.46 $5.66B $23.45 17.98 Medpace $2.53B 7.15 $451.12M $18.04 35.84

Is ELV or MEDP more profitable?

Medpace has a net margin of 18.24% compared to Elevance Health's net margin of 2.55%. Medpace's return on equity of 99.76% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Elevance Health 2.55% 14.97% 5.31% Medpace 18.24% 99.76% 24.47%

Does the media refer more to ELV or MEDP?

In the previous week, Elevance Health had 17 more articles in the media than Medpace. MarketBeat recorded 22 mentions for Elevance Health and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat Elevance Health's score of 0.87 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevance Health 13 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, HIMS or MEDP?

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 1.95 $128.37M -$0.83 N/A Medpace $2.53B 7.15 $451.12M $18.04 35.84

Does the media favor HIMS or MEDP?

In the previous week, Hims & Hers Health had 60 more articles in the media than Medpace. MarketBeat recorded 65 mentions for Hims & Hers Health and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat Hims & Hers Health's score of -0.19 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 2 Very Positive mention(s) 9 Positive mention(s) 23 Neutral mention(s) 23 Negative mention(s) 2 Very Negative mention(s) Neutral Medpace 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.68 $1.36B $8.23 32.20 Medpace $2.53B 7.15 $451.12M $18.04 35.84

Is IQV or MEDP more profitable?

Medpace has a net margin of 18.24% compared to IQVIA's net margin of 8.05%. Medpace's return on equity of 99.76% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.05% 30.02% 6.52% Medpace 18.24% 99.76% 24.47%

Does the media refer more to IQV or MEDP?

In the previous week, IQVIA had 6 more articles in the media than Medpace. MarketBeat recorded 11 mentions for IQVIA and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat IQVIA's score of 0.69 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to A or MEDP?

In the previous week, Agilent Technologies had 7 more articles in the media than Medpace. MarketBeat recorded 12 mentions for Agilent Technologies and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat Agilent Technologies' score of 0.52 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Medpace 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medpace (MEDP) Competitors

$653.94 -2.90 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$654.18 +0.24 (+0.04%)

As of 05:56 PM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and A

Should you buy Medpace stock or one of its competitors? Medpace's main competitors and comparable companies include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Agilent Technologies (A). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Medpace compare to Encompass Health?

Encompass Health (NYSE:EHC) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Encompass Health currently has a consensus target price of $154.25, suggesting a potential upside of 9.74%. Medpace has a consensus target price of $649.27, suggesting a potential upside of 0.42%. Given Encompass Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Medpace has a net margin of 18.24% compared to Encompass Health's net margin of 10.17%. Medpace's return on equity of 99.76% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.17%	18.35%	8.38%
Medpace	18.24%	99.76%	24.47%

97.3% of Encompass Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.8% of Encompass Health shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$5.94B	2.32	$566.20M	$6.40	21.96
Medpace	$2.53B	7.15	$451.12M	$18.04	35.84

Encompass Health has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Medpace has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Encompass Health and Encompass Health both had 5 articles in the media. Medpace's average media sentiment score of 1.29 beat Encompass Health's score of 1.04 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medpace beats Encompass Health on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Elevance Health (NYSE:ELV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Elevance Health had 17 more articles in the media than Medpace. MarketBeat recorded 22 mentions for Elevance Health and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat Elevance Health's score of 0.87 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elevance Health	13 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevance Health	$199.13B	0.46	$5.66B	$23.45	17.98
Medpace	$2.53B	7.15	$451.12M	$18.04	35.84

89.2% of Elevance Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Elevance Health shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Medpace has a net margin of 18.24% compared to Elevance Health's net margin of 2.55%. Medpace's return on equity of 99.76% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elevance Health	2.55%	14.97%	5.31%
Medpace	18.24%	99.76%	24.47%

Elevance Health has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Medpace has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Elevance Health presently has a consensus target price of $456.48, suggesting a potential upside of 8.29%. Medpace has a consensus target price of $649.27, suggesting a potential upside of 0.42%. Given Elevance Health's stronger consensus rating and higher probable upside, analysts plainly believe Elevance Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevance Health	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.68
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

Elevance Health and Medpace tied by winning 8 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Hims & Hers Health had 60 more articles in the media than Medpace. MarketBeat recorded 65 mentions for Hims & Hers Health and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat Hims & Hers Health's score of -0.19 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	2 Very Positive mention(s)	9 Positive mention(s)	23 Neutral mention(s)	23 Negative mention(s)	2 Very Negative mention(s)	Neutral
Medpace	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market. Comparatively, Medpace has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	1.95	$128.37M	-$0.83	N/A
Medpace	$2.53B	7.15	$451.12M	$18.04	35.84

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medpace has a net margin of 18.24% compared to Hims & Hers Health's net margin of -6.65%. Medpace's return on equity of 99.76% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-6.65%	-9.62%	-1.38%
Medpace	18.24%	99.76%	24.47%

Hims & Hers Health presently has a consensus target price of $31.53, suggesting a potential upside of 60.92%. Medpace has a consensus target price of $649.27, suggesting a potential upside of 0.42%. Given Hims & Hers Health's higher probable upside, research analysts plainly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

Medpace beats Hims & Hers Health on 12 of the 15 factors compared between the two stocks.

How does Medpace compare to IQVIA?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

In the previous week, IQVIA had 6 more articles in the media than Medpace. MarketBeat recorded 11 mentions for IQVIA and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat IQVIA's score of 0.69 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Medpace has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.68	$1.36B	$8.23	32.20
Medpace	$2.53B	7.15	$451.12M	$18.04	35.84

89.6% of IQVIA shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Medpace has a net margin of 18.24% compared to IQVIA's net margin of 8.05%. Medpace's return on equity of 99.76% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.05%	30.02%	6.52%
Medpace	18.24%	99.76%	24.47%

IQVIA presently has a consensus target price of $294.21, indicating a potential upside of 11.01%. Medpace has a consensus target price of $649.27, indicating a potential upside of 0.42%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

IQVIA beats Medpace on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Agilent Technologies has a net margin of 19.53% compared to Medpace's net margin of 18.24%. Medpace's return on equity of 99.76% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Medpace	18.24%	99.76%	24.47%

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agilent Technologies has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Medpace has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Medpace. Agilent Technologies is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	7.00	$1.30B	$5.08	33.94
Medpace	$2.53B	7.15	$451.12M	$18.04	35.84

In the previous week, Agilent Technologies had 7 more articles in the media than Medpace. MarketBeat recorded 12 mentions for Agilent Technologies and 5 mentions for Medpace. Medpace's average media sentiment score of 1.29 beat Agilent Technologies' score of 0.52 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Medpace	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies currently has a consensus price target of $181.45, indicating a potential upside of 5.23%. Medpace has a consensus price target of $649.27, indicating a potential upside of 0.42%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Agilent Technologies is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.82
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

Agilent Technologies and Medpace tied by winning 8 of the 16 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.29B	$11.00B	$7.86B	$12.09B
Dividend Yield	N/A	1.45%	2.46%	4.50%
P/E Ratio	36.25	52.35	34.60	30.52
Price / Sales	7.23	8.14	8.89	5.88
Price / Cash	39.07	27.09	22.23	22.80
Price / Book	31.27	4.59	4.40	3.79
Net Income	$451.12M	$57.48B	$3.51B	$390.55M
7 Day Performance	0.13%	-0.09%	-1.50%	-0.30%
1 Month Performance	7.22%	0.46%	-3.92%	-6.64%
1 Year Performance	10.59%	20.11%	0.90%	-5.77%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	2.6369 of 5 stars	$653.94 -0.4%	$649.27 -0.7%	+9.9%	$18.29B	$2.53B	36.25	6,200	Positive News
EHC Encompass Health	4.2383 of 5 stars	$140.79 +2.4%	$154.25 +9.6%	+22.4%	$13.84B	$5.94B	22.00	42,000	Positive News
ELV Elevance Health	4.6489 of 5 stars	$417.73 -1.9%	$456.48 +9.3%	+31.2%	$93.81B	$199.13B	14.31	97,100	Positive News Analyst Forecast
HIMS Hims & Hers Health	2.8953 of 5 stars	$22.90 -11.9%	$32.43 +41.6%	-49.3%	$6.22B	$2.35B	N/A	2,442	Trending News Earnings Report Analyst Forecast Gap Down High Trading Volume
IQV IQVIA	3.8502 of 5 stars	$278.84 +2.6%	$294.21 +5.5%	+22.6%	$43.47B	$16.31B	22.78	93,000	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and A

How does Medpace compare to Encompass Health?

Do analysts prefer EHC or MEDP?

Is EHC or MEDP more profitable?

Do insiders & institutionals hold more shares of EHC or MEDP?

Which has better valuation and earnings, EHC or MEDP?

Which has more volatility and risk, EHC or MEDP?

Does the media favor EHC or MEDP?

Summary

How does Medpace compare to Elevance Health?

Does the media refer more to ELV or MEDP?

Which has preferable valuation & earnings, ELV or MEDP?

Do institutionals & insiders believe in ELV or MEDP?

Is ELV or MEDP more profitable?

Which has more risk and volatility, ELV or MEDP?

Do analysts rate ELV or MEDP?

Summary

How does Medpace compare to Hims & Hers Health?

Does the media favor HIMS or MEDP?

Which has more risk and volatility, HIMS or MEDP?

Which has stronger earnings and valuation, HIMS or MEDP?

Do insiders and institutionals hold more shares of HIMS or MEDP?

Is HIMS or MEDP more profitable?

Do analysts prefer HIMS or MEDP?

Summary

How does Medpace compare to IQVIA?

Does the media refer more to IQV or MEDP?

Which has more volatility & risk, IQV or MEDP?

Which has higher valuation and earnings, IQV or MEDP?

Do institutionals & insiders have more ownership in IQV or MEDP?

Is IQV or MEDP more profitable?

Do analysts recommend IQV or MEDP?

Summary

How does Medpace compare to Agilent Technologies?

Is A or MEDP more profitable?

Do insiders and institutionals believe in A or MEDP?

Which has more volatility & risk, A or MEDP?

Which has preferable valuation and earnings, A or MEDP?

Does the media refer more to A or MEDP?

Do analysts rate A or MEDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools